Dr Natasa Gisev and Associate Professor Amy Peacock ran this online NDARC HDR scholarship information session on Mon, 24 October (12-1 pm).
Shared decision making is the foundation of modern patient-centred care and is key to overcoming patient- and clinical-level barriers to opiate agonist therapy (OAT) uptake and retention in treatme
In this webinar, NDARC’s higher degree research (HDR) candidates give a series of presentations on their thesis topics and results so far.
COVID-19 has forced dramatic changes in the delivery of mental health and alcohol and other drug services.
Pregabalin is a gamma‐aminobutyric acid analogue registered and subsidised for the treatment of neuropathic pain in Australia.
Alprazolam is a high potency triazolobenzodiazepine that is approved in Australia for the treatment of anxiety and panic disorders, however, is associated with a disproportionate amount of harm com
This presentation gives an overview of fatal and non-fatal overdose from the 2019 Drug Trends data, including naloxone knowledge and training of the IDRS sample.
People who use drugs are encouraged to employ harm reduction strategies to reduce risk of acute adverse effects.
Regular Drug Trend monitoring has been vital for Australia since 1999, but has focussed almost exclusively on State and Territory capital cities.
In Australia, ecstasy is one of the most commonly used illicit drugs.